At study end point , LS BMD had significantly increased from baseline in the risedronate group ( P < 0.05 ) but remained unchanged in the placebo group ( mean [ SE ] % Delta , +4.49 % [ 0.38 % ] and +0.05 % [ 0.54 % ] , respectively ; P < 0.001 ) .
